Copper Peptides: Research-Grade GHK-Cu vs Cosmetic Formulations
Research Use Only. This article is written for laboratory and research professionals. The compounds discussed are supplied strictly for in-vitro laboratory research. They are not drugs, dietary supplements, or foods. They are not for human or veterinary use, and not for diagnostic or therapeutic use. Nothing here is medical, legal, or regulatory advice.
The short answer
"Copper peptide" is a category label, not a specification. In cosmetic ingredient labelling it usually means copper tripeptide-1, the INCI name for the copper(II) complex of glycyl-L-histidyl-L-lysine. A characterised research reagent bearing the same chemical name is a different material in every respect that matters: form, concentration, matrix, analytical documentation, and the regulatory category it is supplied under. This article explains why those categories are distinct. It does not recommend any use of either, and contains no guidance on applying anything to a person.
One molecule, two supply categories
The chemistry is common ground. Both categories trace to the same species: a tripeptide, Gly-His-Lys, coordinating a single Cu(II) ion through a nitrogen-rich site. PubChem catalogues it under CAS number 89030-95-5, with the INCI name copper tripeptide-1, the nonproprietary substance name prezatide copper, and the familiar shorthand GHK-Cu. The structure and coordination chemistry are covered in detail separately.
Everything downstream of that molecular identity diverges. A cosmetic ingredient is characterised well enough for its use in a consumer product. A research reagent is characterised well enough that an experiment using it can be interpreted and repeated. Those are different standards, aimed at different failure modes, and neither is a defective version of the other.
The conflation is understandable. Retail and catalogue listings render the name inconsistently: copper peptide, copper peptide serum, GHK Cu, topical GHK-Cu, GHK-Cu face cream, copper tripeptide-1. None of those strings is a specification. A search for "copper peptide" returns serums and research vials on the same page, both saying GHK-Cu, and nothing on the surface explains the difference in price or format. What follows is that explanation.
What "copper peptide" means on a cosmetic label
INCI naming
Cosmetic ingredient lists in the United States are governed by 21 CFR 701.3, which requires ingredients to be declared by their established names in descending order of predominance, with ingredients present at 1 percent or less permitted to appear in any order after the ingredients above that threshold. The naming convention used is INCI, the International Nomenclature of Cosmetic Ingredients.
INCI names are standardised labelling names, not specifications. "Copper tripeptide-1" tells a reader which chemical entity is nominally present. It does not state purity, salt form, counterion, copper stoichiometry, actual concentration, or the analytical method used to confirm any of it.
Related names on the same shelf describe genuinely different molecules. Palmitoyl tripeptide-1 is a lipid-modified peptide with a palmitic acid chain on the lysine side chain, reported at a molecular mass of 578.8 Da against 340.4 Da for GHK, with a very different partition coefficient. It is not GHK-Cu with a marketing name; the N-terminal and side-chain chemistry that governs copper binding has been altered.
What a copper peptide serum discloses
A formulated product discloses its ingredient list and little else. What it does not disclose, typically:
- the concentration of copper tripeptide-1, beyond its position in the list relative to the 1 percent line,
- the purity of the raw material as supplied to the formulator,
- the counterion and net peptide content,
- whether copper is fully complexed or partly free in the finished matrix,
- the analytical release specification, if any, for the peptide in the final product.
None of that is a criticism of cosmetic manufacturing. Consumer products are not analytical standards, and disclosure at that level has never been the expectation. It does mean a formulated product cannot substitute for a characterised reagent, because the quantity you would need to know is exactly the quantity not stated.
What a characterised research reagent means
A research-grade material is defined by its documentation as much as by its contents. The set that makes a peptide interpretable in an experiment:
| Field | What it establishes |
|---|---|
| Sequence and identity | The molecule is what the label says, confirmed by mass spectrometry against theoretical mass |
| HPLC purity | Percentage of peptide-related material represented by the main peak, with the chromatogram supplied |
| Net peptide content | How much of the vial mass is peptide, as distinct from counterion, water and residual salts |
| Counterion | Acetate, trifluoroacetate or other, which changes mass, hygroscopicity and assay behaviour |
| Copper content | Elemental determination confirming stoichiometry rather than assuming it |
| Water content | Residual moisture in the lyophilized cake, which drives stability |
| Lot number and date | Traceability from result back to material |
| Storage condition and retest date | The conditions under which the stated figures hold |
Two of those fields do the heavy lifting. Net peptide content is why gross vial mass is not molar quantity: a nominal 50 mg can contain substantially less peptide once counterion and water are subtracted, and an experiment run at picomolar to nanomolar concentrations cannot absorb that error. Lot traceability is why a result can be defended: without it, an experiment that fails to replicate has no way to distinguish a biological difference from a material difference.
A cosmetic serum has none of these fields, and there is no reason it should. That is the entire point of the distinction.
Format: lyophilized powder against a finished matrix
A research vial contains a sealed, lyophilized cake: peptide dried by sublimation under vacuum, typically with low single-digit residual moisture, in an inert headspace. Dry, cold and dark, it is the most stable form the molecule takes.
A serum or cream is an aqueous or emulsified system containing water, humectants, preservatives, chelating agents, pH adjusters, thickeners, fragrance, and often a dozen more components. Every one of those is a potential interaction partner for a metal complex. The formulation exists to keep the product physically stable, microbiologically controlled and pleasant to handle across two or three years on a shelf: legitimate goals, but not the goal of holding a defined chemical species at a defined concentration.
This is why "just use the serum" fails as a laboratory shortcut: you would add an uncharacterised multi-component matrix alongside an unknown quantity of the compound you meant to test.
Formulation chemistry: why the matrix changes the molecule
The coordination chemistry that makes GHK-Cu interesting also makes it sensitive to its surroundings.
pH governs whether the complex exists. Copper binding requires deprotonation of a backbone amide nitrogen, a pH-dependent step. Below the relevant transition the site does not assemble; well above neutral the geometry rearranges. A formulation's pH is therefore not a cosmetic detail, it determines the speciation of the active ingredient.
Competing ligands dissociate it. Chelators are routine in cosmetic formulation, where they sequester trace metals to protect other ingredients from metal-catalysed oxidation. A chelator that binds copper competes directly with the peptide for it. So do thiols and strong reducing agents, which can reduce Cu(II) to Cu(I) and change the coordination preference entirely.
Basic and oxidative conditions degrade it fastest. Badenhorst, Svirskis and Wu put the complex through forced-degradation conditions in a preformulation study of GHK-Cu for dermal delivery, quantifying it by a stability-indicating reversed-phase HPLC method. GHK-Cu proved susceptible to hydrolytic cleavage under basic and oxidative stress, and to a lesser extent under acidic stress, with first-order degradation profiles. It was stable in water and in pH 4.5 to 7.4 buffers for at least two weeks at 60 °C. HPLC with mass spectrometry identified three degradation products, one of them free histidine, the residue carrying the imidazole donor.
The same study found the complex compatible with Span 60 niosomes but less stable in the presence of the anionic lipid dicetyl phosphate. Excipients are not inert with respect to a metal complex.
Physical chemistry limits transport across an intact barrier. That study reported distribution coefficients (log D) between −2.38 and −2.49 across pH 4.5 to 7.4, placing GHK-Cu firmly on the hydrophilic side. A 2025 review of GHK formulation and permeation work sets that against the usual heuristics for passive permeation of the stratum corneum: a molecular mass below roughly 500 Da is favourable, while a strongly negative logP and a permanent charge at physiological pH are not. That mismatch is why the formulation literature is preoccupied with carriers: work on liposomal encapsulation of GHK-Cu, for instance, reports encapsulation efficiencies of roughly 20 to 32 percent for anionic and cationic liposome systems hydrated at pH 6.0.
Those are measurements of formulation behaviour, reported here as chemistry. They are not statements about what any product does for anyone.
Regulatory framing: three categories, three different tests
This is where the distinction stops being a matter of quality and becomes a matter of law.
Cosmetics
Under the Federal Food, Drug, and Cosmetic Act, a cosmetic is defined by its intended use: articles intended to be rubbed, poured, sprinkled or sprayed on, introduced into, or otherwise applied to the human body for cleansing, beautifying, promoting attractiveness, or altering the appearance. The statutory definitions sit at 21 U.S.C. 321. Cosmetic products and ingredients other than colour additives do not require premarket approval, and the Modernization of Cosmetics Regulation Act of 2022 added facility registration, product listing, adverse event reporting and safety substantiation requirements without changing that basic structure.
Research reagents
Research-use-only material occupies a narrower position than most catalogues imply. The RUO labelling provision lives at 21 CFR 809.10, inside the part governing in vitro diagnostic products for human use. It is a labelling exemption for genuine IVD reagents in a research phase. There is no parallel drug-side RUO exemption anywhere in the Act. An RUO label describes the conditions of supply. It is not a determination of legal status, and it confers no exemption from the rest of the statute.
Drugs
A drug is likewise defined by intended use: articles intended to diagnose, cure, mitigate, treat or prevent disease, or intended to affect the structure or any function of the body. Intended use is judged objectively, from claims, labelling, advertising and other evidence. FDA's own guidance on whether a product is a cosmetic, a drug, or both sets this out plainly: the same physical product can be one, the other, or both, depending on what is claimed for it.
The practical consequence for anyone publishing about copper peptides: the category is set by what is said, not by what is in the bottle.
Where GHK-Cu sits in compounding policy
One piece of the record is worth stating precisely, because it is routinely misreported. The binding list of bulk drug substances usable in compounding under section 503A, 21 CFR 216.23, contains six substances. None of them is a peptide, and the list has been unchanged since 2019.
Separately, FDA maintains an interim policy sorting nominated substances into three categories pending evaluation. GHK-Cu appears in Category 1, and the entry carries a restriction by product form. Category 1 describes enforcement posture during evaluation, not approval and not inclusion on the binding list. An advisory committee recommendation, of the kind issued in 2026, is likewise non-binding: it is not a proposed rule, not a final rule, and not an approval. No peptide "became legal" through any of these steps.
A cosmetic claim is not a research claim
The two categories generate different kinds of statements, and mixing them is where compliance problems start.
A cosmetic claim is about appearance, is made for a finished product, and is substantiated by the manufacturer under the cosmetic standard. A research finding is about a measured endpoint in a defined model, is made for a chemical entity, and is substantiated by a published method someone else can repeat.
Neither converts into the other. A cell-culture result does not license a consumer claim. A consumer product's marketing does not become evidence about the molecule. And a research supplier that borrows cosmetic phrasing has, by the objective-intent test, said something about intended use that the RUO label will not cure.
Side by side
| Cosmetic formulation | Research reagent | |
|---|---|---|
| Named as | Copper tripeptide-1 (INCI) | GHK-Cu, with CAS and sequence |
| Physical form | Aqueous or emulsified finished product | Sealed lyophilized powder |
| Concentration | Not disclosed beyond ingredient order | Stated by mass with net peptide content |
| Purity data | Not supplied to the buyer | HPLC chromatogram and mass spectrum, per lot |
| Other components | Preservatives, chelators, surfactants, fragrance | None, beyond counterion and residual moisture |
| Stability basis | Shelf life of the formulated product | Storage condition and retest date for the compound |
| Traceability | Batch code on the carton | Lot number tied to a certificate of analysis |
| Regulatory category | Cosmetic under the FD&C Act | Laboratory reagent supplied for in-vitro research |
The row that matters most is the third. Everything else follows from not knowing the concentration.
Choosing material for laboratory work
If the work is an experiment, the requirement is a characterised chemical entity with lot-level documentation, and nothing else will do. Research-grade GHK-Cu sits alongside the rest of the peptide catalog, all of it supplied strictly for in-vitro laboratory use and none of it for use on a person.
What the published studies actually measured, and in which models, is a separate question answered in the research literature review.
Working with this material
The certificate of analysis for GHK-Cu, from Horizon Analytical, is on the product page and on Lab results. Our own lot records appear at the lot lookup as lots are released. Supplied for laboratory research use only. Not for human or veterinary use.
Compliance notice. Nothing in this article should be read as guidance for administering any compound to a human or animal subject. "Research Use Only" describes the conditions under which a material is supplied; it is not a determination of legal status and confers no exemption from the Federal Food, Drug, and Cosmetic Act. Researchers are responsible for compliance with all applicable federal, state, and institutional requirements, and for obtaining any approvals their work requires.
Frequently asked questions
What is copper tripeptide-1?
Copper tripeptide-1 is the INCI labelling name for the copper(II) complex of glycyl-L-histidyl-L-lysine, the same chemical entity referred to in the research literature as GHK-Cu. It is catalogued under CAS number 89030-95-5. The INCI name identifies the ingredient for labelling purposes and states nothing about purity, concentration or analytical characterisation.
Is a copper peptide serum the same as research-grade GHK-Cu?
No. They may contain the same named chemical entity, but they differ in physical form, concentration, matrix components, analytical documentation and regulatory category. A serum is a finished multi-component product with an undisclosed concentration; a research reagent is a lyophilized powder supplied with lot-specific purity, identity and net peptide content data.
Why does a cosmetic ingredient list not state the concentration?
United States cosmetic labelling requires ingredients to be declared in descending order of predominance, with anything at 1 percent or less permitted in any order below that threshold. The rule discloses approximate ranking, not quantity. That is sufficient for consumer labelling and insufficient for an experiment, where molar concentration is the variable being controlled.
What affects GHK-Cu stability in a formulation?
pH determines whether the copper site assembles at all, because complex formation requires deprotonation of a backbone amide nitrogen. Competing chelators and reducing agents can strip or reduce the metal. In published forced-degradation testing, basic and oxidative conditions degraded it fastest, with acidic stress having less impact, while the complex remained stable in water and in pH 4.5 to 7.4 buffers for at least two weeks at 60 °C.
Is topical GHK-Cu absorbed through the skin?
The formulation literature treats that as an open measurement problem rather than a settled fact. GHK-Cu has a molecular mass near 340 Da for the peptide, below the usual heuristic cutoff, but distribution coefficients between −2.38 and −2.49 and a permanent charge at physiological pH both work against passive permeation. That mismatch is why published work focuses on carrier systems such as liposomes and on how permeation should be measured.
Is GHK-Cu a drug?
Not by category. Under the Federal Food, Drug, and Cosmetic Act, drug status is determined by intended use, judged objectively from claims, labelling and advertising rather than from the molecule itself. The binding 503A bulk substances list at 21 CFR 216.23 contains six substances, none of them peptides, and GHK-Cu is not an approved drug.
Can research-grade material be used in a cosmetic formulation?
That question sits outside the scope of this article, which addresses how the two categories differ rather than how to move between them. Material supplied as a research reagent is supplied for in-vitro laboratory research only, and its documentation is written for that purpose.
Primary sources
The remaining literature cited above, for direct verification:
- work on liposomal encapsulation of GHK-Cu: https://pmc.ncbi.nlm.nih.gov/articles/PMC10610410/
- 21 U.S.C. 321: https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section321
- Modernization of Cosmetics Regulation Act of 2022: https://www.fda.gov/cosmetics/cosmetics-laws-regulations/modernization-cosmetics-regulation-act-2022-mocra
- 21 CFR 809.10: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-809/section-809.10
- whether a product is a cosmetic, a drug, or both: https://www.fda.gov/cosmetics/cosmetics-laws-regulations/it-cosmetic-drug-or-both-or-it-soap
- 21 CFR 216.23: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-216/section-216.23
- three categories pending evaluation: https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
